NASDAQ:REGN Regeneron Pharmaceuticals (REGN) Stock Price, News & Analysis $931.78 -9.61 (-1.02%) (As of 04:02 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Regeneron Pharmaceuticals Stock (NASDAQ:REGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Key Stats Today's Range$930.35▼$947.0950-Day Range$941.39▼$1,201.7652-Week Range$769.19▼$1,211.20Volume338,750 shsAverage Volume503,600 shsMarket Capitalization$102.72 billionP/E Ratio24.68Dividend YieldN/APrice Target$1,102.19Consensus RatingModerate Buy Company OverviewRegeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.Read More… The gold trades I'm making right now (Ad)Back in November, gold made a tiny move of 1.6%. But using a special type of gold trade, I saw a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there were smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period.It's all about catching what I call "Acceleration Cycles." Regeneron Pharmaceuticals Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks95th Percentile Overall ScoreREGN MarketRank™: Regeneron Pharmaceuticals scored higher than 95% of companies evaluated by MarketBeat, and ranked 66th out of 1,001 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingRegeneron Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on 17 buy ratings, 4 hold ratings, and 1 sell rating.Amount of Analyst CoverageRegeneron Pharmaceuticals has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Regeneron Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth5.05% Earnings GrowthEarnings for Regeneron Pharmaceuticals are expected to grow by 5.05% in the coming year, from $37.66 to $39.56 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Regeneron Pharmaceuticals is 24.79, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.98.Price to Earnings Ratio vs. SectorThe P/E ratio of Regeneron Pharmaceuticals is 24.79, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 134.46.Price to Earnings Growth RatioRegeneron Pharmaceuticals has a PEG Ratio of 3.29. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioRegeneron Pharmaceuticals has a P/B Ratio of 3.96. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Regeneron Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.57% of the outstanding shares of Regeneron Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRegeneron Pharmaceuticals has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Regeneron Pharmaceuticals has recently decreased by 12.63%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRegeneron Pharmaceuticals does not currently pay a dividend.Dividend GrowthRegeneron Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG2.3 / 5Environmental Score-2.69 Percentage of Shares Shorted1.57% of the outstanding shares of Regeneron Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverRegeneron Pharmaceuticals has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Regeneron Pharmaceuticals has recently decreased by 12.63%, indicating that investor sentiment is improving significantly. News and Social Media3.6 / 5News Sentiment0.52 News SentimentRegeneron Pharmaceuticals has a news sentiment score of 0.52. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 31 news articles for Regeneron Pharmaceuticals this week, compared to 16 articles on an average week.Search Interest34 people have searched for REGN on MarketBeat in the last 30 days. This is an increase of 162% compared to the previous 30 days.MarketBeat Follows18 people have added Regeneron Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Regeneron Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,367,364.00 in company stock.Percentage Held by InsidersOnly 7.48% of the stock of Regeneron Pharmaceuticals is held by insiders.Percentage Held by Institutions83.31% of the stock of Regeneron Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Regeneron Pharmaceuticals' insider trading history. REGN Stock News HeadlinesThese 3 Stocks Are Screaming Oversold: Seize the Opportunity (REGN)Micron, Biogen, and Regeneron are three stocks that appear oversold and could present substantial buying opportunities for investors seeking recovery plays.October 10, 2024 | marketbeat.comRegeneron: Buy Rating Reaffirmed Amid Eylea Biosimilar Challenge and Pipeline StrengthOctober 24 at 2:37 PM | markets.businessinsider.comUnlock the Secret to Earning Consistent Income from Stocks Under $30!Are you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE!October 24, 2024 | Darwin (Ad)$100 Invested In This Stock 15 Years Ago Would Be Worth $5,800 TodayOctober 24 at 2:37 PM | benzinga.comRegeneron Pharmaceuticals, Inc.: Dupixent (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAIOctober 24 at 9:35 AM | finanznachrichten.dePress Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAIOctober 24 at 8:00 AM | globenewswire.comDupixent® (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAIOctober 24 at 8:00 AM | globenewswire.comStrategic Buy Rating for Regeneron Amid Competitive Challenges with Long-Term Growth PotentialOctober 23 at 11:32 PM | markets.businessinsider.comSee More Headlines REGN Stock Analysis - Frequently Asked Questions How have REGN shares performed this year? Regeneron Pharmaceuticals' stock was trading at $878.29 at the beginning of the year. Since then, REGN stock has increased by 6.6% and is now trading at $936.10. View the best growth stocks for 2024 here. How were Regeneron Pharmaceuticals' earnings last quarter? Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) announced its quarterly earnings results on Thursday, August, 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, topping analysts' consensus estimates of $8.93 by $2.63. The firm's quarterly revenue was up 12.3% on a year-over-year basis. Read the conference call transcript. Does Regeneron Pharmaceuticals have any subsidiaries? The following companies are subsidiaries of Regeneron Pharmaceuticals: Eastside Campus Holdings LLC, Loop Road Holdings LLC, Old Saw Mill Holdings LLC, OSMR Holdings, Regeneron Assurance Inc., Regeneron Atlantic Holdings, Regeneron Belgium BV, and others. Who are Regeneron Pharmaceuticals' major shareholders? Top institutional investors of Regeneron Pharmaceuticals include International Assets Investment Management LLC (0.80%), DekaBank Deutsche Girozentrale (0.19%), Assenagon Asset Management S.A. (0.16%) and Swedbank AB (0.14%). Insiders that own company stock include George Yancopoulos, Leonard S Schleifer, Neil Stahl, Andrew J Murphy, Joseph J Larosa, Robert E Landry, Plew Daniel P Van, Arthur F Ryan, Christopher R Fenimore, Marion Mccourt, Joseph L Goldstein, Jason Pitofsky, Marc Tessier-Lavigne, Christine A Poon, Michael S Brown, Bonnie L Bassler, Huda Y Zoghbi, N Anthony Coles and George L Sing. View institutional ownership trends. How do I buy shares of Regeneron Pharmaceuticals? Shares of REGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Regeneron Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Regeneron Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V). Company Calendar Last Earnings8/01/2024Today10/24/2024Next Earnings (Confirmed)10/31/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:REGN CUSIP75886F10 CIK872589 Webwww.regeneron.com Phone(914) 847-7000Fax914-347-2113Employees13,450Year Founded1988Price Target and Rating Average Stock Price Target$1,102.19 High Stock Price Target$1,300.00 Low Stock Price Target$720.00 Potential Upside/Downside+17.1%Consensus RatingModerate Buy Rating Score (0-4)2.77 Research Coverage22 Analysts Profitability EPS (Most Recent Fiscal Year)$33.85 Trailing P/E Ratio24.93 Forward P/E Ratio25.04 P/E Growth3.4Net Income$3.95 billion Net Margins32.04% Pretax Margin34.01% Return on Equity16.80% Return on Assets13.13% Debt Debt-to-Equity Ratio0.10 Current Ratio5.44 Quick Ratio4.62 Sales & Book Value Annual Sales$13.49 billion Price / Sales7.69 Cash Flow$41.11 per share Price / Cash Flow22.90 Book Value$236.63 per share Price / Book3.98Miscellaneous Outstanding Shares110,186,000Free Float101,989,000Market Cap$103.73 billion OptionableOptionable Beta0.12 Social Links This page (NASDAQ:REGN) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | SponsoredNext opportunity for crypto millionsAccording to Steven Lubka, head of a private equity firm with over $250M in assets under management, "Bitcoin ...Crypto 101 Media | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredAmerica’s Election NightmareThanks to a new law signed by President Biden, a small group of powerful people could decide who is installed ...Banyan Hill Publishing | SponsoredIt’s delivered 859% in 2.5 months…We’ve gotten a lot of messages asking… what should we buy if Trump wins? What should we buy if Kamala wins?...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist My Default Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Share Regeneron Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
